Minocycline in Huntington's disease: A pilot study
Minocycline is a caspase inhibitor, decreases inducible nitric oxide synthase (iNOS), and has been shown to delay disease progression in the mouse model R6/2 of Huntington's disease (HD). This safety and tolerability study included 30 patients with HD who were given minocycline over a 6‐month p...
Gespeichert in:
| Veröffentlicht in: | Movement disorders 2004-06, Vol.19 (6), p.692-695 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 695 |
|---|---|
| container_issue | 6 |
| container_start_page | 692 |
| container_title | Movement disorders |
| container_volume | 19 |
| creator | Thomas, Madhavi Ashizawa, Tetsuo Jankovic, Joseph |
| description | Minocycline is a caspase inhibitor, decreases inducible nitric oxide synthase (iNOS), and has been shown to delay disease progression in the mouse model R6/2 of Huntington's disease (HD). This safety and tolerability study included 30 patients with HD who were given minocycline over a 6‐month period and underwent assessments every 2 months with laboratory studies, the Abnormal Involuntary Movements Scale, the Unified Huntington's Disease Rating Scale, and the Mini‐Mental State Examination. Minocycline was well tolerated during this study period and no serious adverse events were noted. © 2004 Movement Disorder Society |
| doi_str_mv | 10.1002/mds.20018 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72030561</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21127389</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4488-64f662928fc96263278277ea775d3b6ee083f37861164ef1422d752bad56f84d3</originalsourceid><addsrcrecordid>eNqF0EtLw0AUBeBBFFsfC_-AZKPiIu08Mo-4K_VRocWFuh6m85CRdFIzCZJ_b2oCuhFXZ_NxD_cAcIbgBEGIpxsTJxhCJPbAGFGCUoEp3wdjKARNCRJ0BI5ifO8EoogdglEXOecIjgFe-VDqVhc-2MSHZNGE2oe3ugxXMTE-WhXtTTJLtr4o6yTWjWlPwIFTRbSnQx6D1_u7l_kiXT49PM5ny1RnmRApyxxjOMfC6ZxhRjAXmHOrOKeGrJm1UBBHuGAIscw6lGFsOMVrZShzIjPkGFz2d7dV-dHYWMuNj9oWhQq2bKLkGBJIGfoXYoQwJyLv4HUPdVXGWFknt5XfqKqVCMrdkrJbUn4v2dnz4Wiz3ljzI4fpOnAxABW1Klylgvbxl-u-hvnOTXv36Qvb_t0oV7fPffUXXC6G5g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21127389</pqid></control><display><type>article</type><title>Minocycline in Huntington's disease: A pilot study</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Thomas, Madhavi ; Ashizawa, Tetsuo ; Jankovic, Joseph</creator><creatorcontrib>Thomas, Madhavi ; Ashizawa, Tetsuo ; Jankovic, Joseph</creatorcontrib><description>Minocycline is a caspase inhibitor, decreases inducible nitric oxide synthase (iNOS), and has been shown to delay disease progression in the mouse model R6/2 of Huntington's disease (HD). This safety and tolerability study included 30 patients with HD who were given minocycline over a 6‐month period and underwent assessments every 2 months with laboratory studies, the Abnormal Involuntary Movements Scale, the Unified Huntington's Disease Rating Scale, and the Mini‐Mental State Examination. Minocycline was well tolerated during this study period and no serious adverse events were noted. © 2004 Movement Disorder Society</description><identifier>ISSN: 0885-3185</identifier><identifier>EISSN: 1531-8257</identifier><identifier>DOI: 10.1002/mds.20018</identifier><identifier>PMID: 15197710</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Aged ; apoptosis ; Biological and medical sciences ; caspase inhibition ; Caspase Inhibitors ; Cognition Disorders - diagnosis ; Cognition Disorders - etiology ; Enzyme Inhibitors - therapeutic use ; Female ; Humans ; Huntington Disease - complications ; Huntington Disease - drug therapy ; Huntington Disease - enzymology ; Huntington's disease ; Male ; Medical sciences ; Middle Aged ; minocycline ; Minocycline - therapeutic use ; Neurology ; neuroprotection ; Neuropsychological Tests ; Nitric Oxide Synthase - metabolism ; Nitric Oxide Synthase Type II ; Pilot Projects</subject><ispartof>Movement disorders, 2004-06, Vol.19 (6), p.692-695</ispartof><rights>Copyright © 2004 Movement Disorder Society</rights><rights>2004 INIST-CNRS</rights><rights>Copyright 2004 Movement Disorder Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4488-64f662928fc96263278277ea775d3b6ee083f37861164ef1422d752bad56f84d3</citedby><cites>FETCH-LOGICAL-c4488-64f662928fc96263278277ea775d3b6ee083f37861164ef1422d752bad56f84d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fmds.20018$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fmds.20018$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15962090$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15197710$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Thomas, Madhavi</creatorcontrib><creatorcontrib>Ashizawa, Tetsuo</creatorcontrib><creatorcontrib>Jankovic, Joseph</creatorcontrib><title>Minocycline in Huntington's disease: A pilot study</title><title>Movement disorders</title><addtitle>Mov Disord</addtitle><description>Minocycline is a caspase inhibitor, decreases inducible nitric oxide synthase (iNOS), and has been shown to delay disease progression in the mouse model R6/2 of Huntington's disease (HD). This safety and tolerability study included 30 patients with HD who were given minocycline over a 6‐month period and underwent assessments every 2 months with laboratory studies, the Abnormal Involuntary Movements Scale, the Unified Huntington's Disease Rating Scale, and the Mini‐Mental State Examination. Minocycline was well tolerated during this study period and no serious adverse events were noted. © 2004 Movement Disorder Society</description><subject>Adult</subject><subject>Aged</subject><subject>apoptosis</subject><subject>Biological and medical sciences</subject><subject>caspase inhibition</subject><subject>Caspase Inhibitors</subject><subject>Cognition Disorders - diagnosis</subject><subject>Cognition Disorders - etiology</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Huntington Disease - complications</subject><subject>Huntington Disease - drug therapy</subject><subject>Huntington Disease - enzymology</subject><subject>Huntington's disease</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>minocycline</subject><subject>Minocycline - therapeutic use</subject><subject>Neurology</subject><subject>neuroprotection</subject><subject>Neuropsychological Tests</subject><subject>Nitric Oxide Synthase - metabolism</subject><subject>Nitric Oxide Synthase Type II</subject><subject>Pilot Projects</subject><issn>0885-3185</issn><issn>1531-8257</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0EtLw0AUBeBBFFsfC_-AZKPiIu08Mo-4K_VRocWFuh6m85CRdFIzCZJ_b2oCuhFXZ_NxD_cAcIbgBEGIpxsTJxhCJPbAGFGCUoEp3wdjKARNCRJ0BI5ifO8EoogdglEXOecIjgFe-VDqVhc-2MSHZNGE2oe3ugxXMTE-WhXtTTJLtr4o6yTWjWlPwIFTRbSnQx6D1_u7l_kiXT49PM5ny1RnmRApyxxjOMfC6ZxhRjAXmHOrOKeGrJm1UBBHuGAIscw6lGFsOMVrZShzIjPkGFz2d7dV-dHYWMuNj9oWhQq2bKLkGBJIGfoXYoQwJyLv4HUPdVXGWFknt5XfqKqVCMrdkrJbUn4v2dnz4Wiz3ljzI4fpOnAxABW1Klylgvbxl-u-hvnOTXv36Qvb_t0oV7fPffUXXC6G5g</recordid><startdate>200406</startdate><enddate>200406</enddate><creator>Thomas, Madhavi</creator><creator>Ashizawa, Tetsuo</creator><creator>Jankovic, Joseph</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope><scope>8BM</scope></search><sort><creationdate>200406</creationdate><title>Minocycline in Huntington's disease: A pilot study</title><author>Thomas, Madhavi ; Ashizawa, Tetsuo ; Jankovic, Joseph</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4488-64f662928fc96263278277ea775d3b6ee083f37861164ef1422d752bad56f84d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Aged</topic><topic>apoptosis</topic><topic>Biological and medical sciences</topic><topic>caspase inhibition</topic><topic>Caspase Inhibitors</topic><topic>Cognition Disorders - diagnosis</topic><topic>Cognition Disorders - etiology</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Huntington Disease - complications</topic><topic>Huntington Disease - drug therapy</topic><topic>Huntington Disease - enzymology</topic><topic>Huntington's disease</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>minocycline</topic><topic>Minocycline - therapeutic use</topic><topic>Neurology</topic><topic>neuroprotection</topic><topic>Neuropsychological Tests</topic><topic>Nitric Oxide Synthase - metabolism</topic><topic>Nitric Oxide Synthase Type II</topic><topic>Pilot Projects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thomas, Madhavi</creatorcontrib><creatorcontrib>Ashizawa, Tetsuo</creatorcontrib><creatorcontrib>Jankovic, Joseph</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><collection>ComDisDome</collection><jtitle>Movement disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thomas, Madhavi</au><au>Ashizawa, Tetsuo</au><au>Jankovic, Joseph</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Minocycline in Huntington's disease: A pilot study</atitle><jtitle>Movement disorders</jtitle><addtitle>Mov Disord</addtitle><date>2004-06</date><risdate>2004</risdate><volume>19</volume><issue>6</issue><spage>692</spage><epage>695</epage><pages>692-695</pages><issn>0885-3185</issn><eissn>1531-8257</eissn><abstract>Minocycline is a caspase inhibitor, decreases inducible nitric oxide synthase (iNOS), and has been shown to delay disease progression in the mouse model R6/2 of Huntington's disease (HD). This safety and tolerability study included 30 patients with HD who were given minocycline over a 6‐month period and underwent assessments every 2 months with laboratory studies, the Abnormal Involuntary Movements Scale, the Unified Huntington's Disease Rating Scale, and the Mini‐Mental State Examination. Minocycline was well tolerated during this study period and no serious adverse events were noted. © 2004 Movement Disorder Society</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>15197710</pmid><doi>10.1002/mds.20018</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0885-3185 |
| ispartof | Movement disorders, 2004-06, Vol.19 (6), p.692-695 |
| issn | 0885-3185 1531-8257 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72030561 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Aged apoptosis Biological and medical sciences caspase inhibition Caspase Inhibitors Cognition Disorders - diagnosis Cognition Disorders - etiology Enzyme Inhibitors - therapeutic use Female Humans Huntington Disease - complications Huntington Disease - drug therapy Huntington Disease - enzymology Huntington's disease Male Medical sciences Middle Aged minocycline Minocycline - therapeutic use Neurology neuroprotection Neuropsychological Tests Nitric Oxide Synthase - metabolism Nitric Oxide Synthase Type II Pilot Projects |
| title | Minocycline in Huntington's disease: A pilot study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T08%3A13%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Minocycline%20in%20Huntington's%20disease:%20A%20pilot%20study&rft.jtitle=Movement%20disorders&rft.au=Thomas,%20Madhavi&rft.date=2004-06&rft.volume=19&rft.issue=6&rft.spage=692&rft.epage=695&rft.pages=692-695&rft.issn=0885-3185&rft.eissn=1531-8257&rft_id=info:doi/10.1002/mds.20018&rft_dat=%3Cproquest_cross%3E21127389%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=21127389&rft_id=info:pmid/15197710&rfr_iscdi=true |